You are here: Industry Insights > Editor's Picks

News List

Junshi and Eli Lilly have reached a USD 255 million COVID-19 Virus Antibody Authorization Deal CPhI.CN
May 06, 2020
On May 4, Junshi Biosciences and Eli Lilly Pharma announced that the two parties have reached an agreement to jointly develop and commercialize SARS-CoV-2 neutralizing antibodies against new coronary pneumonia caused by the new SARS-CoV-2 coronavirus.
Yangtze River Receiving Another 2 Clinical Trial Implied Permissions CPhI.CN
April 27, 2020
Yangtze River Receiving Another 2 Clinical Trial Implied Permissions in the Battle for the First Generic of the Blockbuster MM Drug Pomalidomide.
Second Indication Application of Novo Nordisk Liraglutide to be Approved in China soon CPhI.CN
May 13, 2020
Novo Nordisk Liraglutide continues to make efforts in China, its second indication application to be approved soon.
New Indication of CSPC Group 's Butylphthalide Soft Capsules Entered Phase III Trial CPhI.CN
May 12, 2020
The Phase III clinical of Butylphthalide Soft Capsules（Trade name: NBP）for the treatment of vascular dementia was officially approved by the Genetics Office in China.
A New Indication of Secukinumab to be Approved in China! PharmaSources/Caicai
April 26, 2020
The marketing application (acceptance No. JXSS1900025) of a new indication of Novartis’ secukinumab in China has recently changed to “Under approval” and is expected to be approved soon. First approved by the NMPA for marketing in Mar. 2019, this will be